JP6875126B2 - 迅速かつ包括的なｔ細胞免疫モニタリング用の細胞プラットフォーム - Google Patents

迅速かつ包括的なｔ細胞免疫モニタリング用の細胞プラットフォーム Download PDF

Info

Publication number
JP6875126B2
JP6875126B2 JP2016546026A JP2016546026A JP6875126B2 JP 6875126 B2 JP6875126 B2 JP 6875126B2 JP 2016546026 A JP2016546026 A JP 2016546026A JP 2016546026 A JP2016546026 A JP 2016546026A JP 6875126 B2 JP6875126 B2 JP 6875126B2
Authority
JP
Japan
Prior art keywords
adjacent
sequence
cells
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016546026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506882A5 (enExample
JP2017506882A (ja
Inventor
ロナルド ディー． ザ サード サイデル
ロナルド ディー． ザ サード サイデル
ロドルフォ チャパーロ
ロドルフォ チャパーロ
ブランダン エス． ヒルリッチ
ブランダン エス． ヒルリッチ
スティーブン シー． アルモ
スティーブン シー． アルモ
Original Assignee
アルバート アインシュタイン カレッジ オブ メディシン
アルバート アインシュタイン カレッジ オブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルバート アインシュタイン カレッジ オブ メディシン, アルバート アインシュタイン カレッジ オブ メディシン filed Critical アルバート アインシュタイン カレッジ オブ メディシン
Publication of JP2017506882A publication Critical patent/JP2017506882A/ja
Publication of JP2017506882A5 publication Critical patent/JP2017506882A5/ja
Application granted granted Critical
Publication of JP6875126B2 publication Critical patent/JP6875126B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016546026A 2014-01-21 2015-01-21 迅速かつ包括的なｔ細胞免疫モニタリング用の細胞プラットフォーム Expired - Fee Related JP6875126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461929651P 2014-01-21 2014-01-21
US61/929,651 2014-01-21
PCT/US2015/012160 WO2015112541A2 (en) 2014-01-21 2015-01-21 Cellular platform for rapid and comprehensive t-cell immunomonitoring

Publications (3)

Publication Number Publication Date
JP2017506882A JP2017506882A (ja) 2017-03-16
JP2017506882A5 JP2017506882A5 (enExample) 2018-03-01
JP6875126B2 true JP6875126B2 (ja) 2021-05-19

Family

ID=53682115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546026A Expired - Fee Related JP6875126B2 (ja) 2014-01-21 2015-01-21 迅速かつ包括的なｔ細胞免疫モニタリング用の細胞プラットフォーム

Country Status (11)

Country Link
US (2) US20170176435A1 (enExample)
EP (1) EP3096774B1 (enExample)
JP (1) JP6875126B2 (enExample)
KR (1) KR102488477B1 (enExample)
CN (1) CN106132428B (enExample)
AU (1) AU2015209540B2 (enExample)
BR (1) BR112016016937A8 (enExample)
CA (1) CA2936352A1 (enExample)
IL (1) IL246685B (enExample)
SG (1) SG11201605632SA (enExample)
WO (1) WO2015112541A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
US11407806B2 (en) 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
CN107099603A (zh) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 肿瘤免疫t细胞检测试剂盒和检测方法
MX2020002596A (es) * 2017-09-07 2020-07-20 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL316576A (en) * 2019-02-12 2024-12-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
CN114127305A (zh) * 2019-05-23 2022-03-01 麻省理工学院 经由逆转录病毒表面展示的配体发现和基因递送
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
EP4281569A4 (en) * 2021-01-25 2025-04-02 The Regents Of The University Of California Methods and compositions for labeling and selecting antigen-specific T cells
CA3212006A1 (en) 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
CA3236366A1 (en) * 2021-10-27 2023-05-04 Xiaojun Lian Universal stem cell and uses thereof
EP4784626A1 (en) 2023-09-25 2026-08-05 Kelonia Therapeutics, Inc. Antigen binding polypeptides
IL327310A (en) 2023-09-25 2026-05-01 Kelonia Therapeutics Inc Cancer treatment vehicles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1430728A (zh) * 2000-05-25 2003-07-16 苏诺尔分子公司 T细胞受体交互作用的调节
WO2002099070A2 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
AU2003901876A0 (en) * 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2007136778A2 (en) * 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Fusion proteins, uses thereof and processes for producing same
EP1889851A1 (en) * 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
HK1211949A1 (en) * 2012-11-30 2016-06-03 罗切格利卡特公司 Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins

Also Published As

Publication number Publication date
AU2015209540B2 (en) 2021-05-13
EP3096774A2 (en) 2016-11-30
IL246685A0 (en) 2016-08-31
KR102488477B1 (ko) 2023-01-13
CA2936352A1 (en) 2015-07-30
US20170176435A1 (en) 2017-06-22
CN106132428A (zh) 2016-11-16
CN106132428B (zh) 2021-08-06
AU2015209540A1 (en) 2016-07-28
WO2015112541A2 (en) 2015-07-30
WO2015112541A8 (en) 2016-09-09
AU2015209540A8 (en) 2016-08-18
JP2017506882A (ja) 2017-03-16
EP3096774B1 (en) 2021-03-24
SG11201605632SA (en) 2016-08-30
EP3096774A4 (en) 2017-09-06
BR112016016937A2 (pt) 2017-08-08
US20230052675A1 (en) 2023-02-16
BR112016016937A8 (pt) 2018-12-18
WO2015112541A3 (en) 2015-12-03
IL246685B (en) 2020-03-31
KR20170002366A (ko) 2017-01-06

Similar Documents

Publication Publication Date Title
KR102488477B1 (ko) 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼
Yu et al. Engineered cell entry links receptor biology with single-cell genomics
JP7048494B2 (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
JP2026026312A (ja) レトロウイルスおよびレンチウイルスベクター
CN103797028B (zh) 使靶细胞可逆染色的方法
RU2740648C2 (ru) Сконструированные высокоаффинные t-клеточные рецепторы человека
US20250027073A1 (en) Methods and compositions for discovery of receptor-ligand specificity by engineered cell entry
JP6718450B2 (ja) キメラ抗原受容体及びその使用方法
Alonso-Camino et al. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors
Truscott et al. Disulfide bond engineering to trap peptides in the MHC class I binding groove
CN112334480A (zh) 肽-MHC comPACT
WO2019023269A1 (en) DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
WO2022047417A1 (en) Anti-idiotype compositions and methods of use thereof
JP2024519500A (ja) 単鎖三量体ｍｈｃクラスｉ核酸およびタンパク質ならびに使用方法
US20220411472A1 (en) Self-assembling circular tandem repeat proteins with increased stability
JP2021536256A (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
CN116981684A (zh) 一种纳米颗粒及其检测car阳性表达率的应用
CN111826398A (zh) 用于活细胞间膜蛋白展示和相互作用检测的工程质粒系统
Yu et al. Systematic discovery of receptor-ligand biology by engineered cell entry and single-cell genomics
Chour Molecular Technologies for Antigen-Based Immunity
CN118369426A (zh) 通过工程化细胞进入发现受体-配体特异性的方法和组合物
Gaglione High-throughput tools for decoding T cell receptor specificity
Gunnels et al. CELLISA–a cell-cell binding assay for evaluation of nanovesicle targeting proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200403

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200512

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200520

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210422

R150 Certificate of patent or registration of utility model

Ref document number: 6875126

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees